FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to the field of pharmaceutics and medicine, namely to a pharmaceutical composition regulating the immune response of a living organism, which is a mixture of a nitrogenous heterocyclic compound and fullerenol, where baricitinib is used as nitrogenous heterocyclic compound, and fullerenol C60 is used as fullerenol.
EFFECT: reducing the level of pro-inflammatory cytokines in a living body.
4 cl, 1 dwg, 4 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION STIMULATING IMMUNE RESPONSE OF LIVING BODY | 2021 |
|
RU2821633C1 |
FULLERENOL PRODUCTION METHOD | 2020 |
|
RU2750604C1 |
COMPOSITION FOR ATOPIC DERMATITIS THERAPY BASED ON FULLEREN | 2016 |
|
RU2641041C1 |
2-(3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-1-(ETHYLSULFONYL)AZETIDIN-3-YL)ACETONITRILE HEMINAPHTHYLDISULFONATE AS JANUS KINASE INHIBITOR | 2016 |
|
RU2644155C1 |
NOVEL PYRROLOPYRIMIDINE DERIVATIVES | 2024 |
|
RU2837215C1 |
NOVEL PYRROLOPYRIMIDINE DERIVATIVES | 2024 |
|
RU2837316C1 |
NOVEL PYRROLOPYRIMIDINE DERIVATIVES | 2024 |
|
RU2837533C1 |
NOVEL PYRROLOPYRIMIDINE DERIVATIVES | 2024 |
|
RU2837548C1 |
NOVEL PYRROLOPYRIMIDINE DERIVATIVES | 2024 |
|
RU2837216C1 |
NOVEL PYRROLOPYRIMIDINE DERIVATIVES | 2024 |
|
RU2837221C1 |
Authors
Dates
2024-09-03—Published
2021-10-29—Filed